Cerebrospinal fluid BACE1 activity and Saβppβ as biomarker candidates of alzheimer's disease

Panagiotis Alexopoulos, Nathalie Thierjung, Timo Grimmer, Marion Ortner, Polychronis Economou, Konstantinos Assimakopoulos, Philippos Gourzis, Antonios Politis, Robert Perneczky

Research output: Contribution to journalArticlepeer-review


Background/Aims: The utility of β-site amyloid-β precursor protein (AβPP) cleaving enzyme 1 (BACE1) activity and soluble AβPP β (sAβPPβ) levels in cerebrospinal fluid (CSF) in detecting Alzheimer's disease (AD) is still elusive. Methods: BACE1 activity and sAβPPβ concentration were measured in patients with AD dementia (n = 56) and mild cognitive impairment (MCI) due to AD (n = 76) with abnormal routine AD CSF markers, in patients with MCI with normal CSF markers (n = 39), and in controls without preclinical AD (n = 48). In a subsample with available 18F-fluorodeoxyglucose positron emission tomography (FDG PET) data, ordinal regression models were employed to compare the contribution of BACE1 and sAβPPβ to correct diagnostic classification to that of FDG PET. Results: BACE1 activity was significantly higher in patients with MCI due to AD compared to both controls and patients with MCI with normal CSF markers. sAβPPβ did not differ between any of the studied groups. Interestingly, BACE1 activity was not found to be inferior to FDG PET as predictive covariate in differentiating between the diagnostic groups. Conclusions: Further studies using biomarker-underpinned diagnoses are warranted to shed more light on the potential diagnostic utility of BACE1 activity as AD biomarker candidate in MCI.

Original languageEnglish (US)
Pages (from-to)152-161
Number of pages10
JournalDementia and Geriatric Cognitive Disorders
Issue number3-4
StatePublished - Jul 1 2018


  • BACE1
  • Biomarker candidate
  • Dementia
  • Mild cognitive impairment
  • sAβPPβ

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Cognitive Neuroscience
  • Psychiatry and Mental health


Dive into the research topics of 'Cerebrospinal fluid BACE1 activity and Saβppβ as biomarker candidates of alzheimer's disease'. Together they form a unique fingerprint.

Cite this